Correlation Between CERo Therapeutics and Cyclacel Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both CERo Therapeutics and Cyclacel Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining CERo Therapeutics and Cyclacel Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between CERo Therapeutics Holdings and Cyclacel Pharmaceuticals, you can compare the effects of market volatilities on CERo Therapeutics and Cyclacel Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in CERo Therapeutics with a short position of Cyclacel Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of CERo Therapeutics and Cyclacel Pharmaceuticals.

Diversification Opportunities for CERo Therapeutics and Cyclacel Pharmaceuticals

-0.11
  Correlation Coefficient

Good diversification

The 3 months correlation between CERo and Cyclacel is -0.11. Overlapping area represents the amount of risk that can be diversified away by holding CERo Therapeutics Holdings and Cyclacel Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cyclacel Pharmaceuticals and CERo Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on CERo Therapeutics Holdings are associated (or correlated) with Cyclacel Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cyclacel Pharmaceuticals has no effect on the direction of CERo Therapeutics i.e., CERo Therapeutics and Cyclacel Pharmaceuticals go up and down completely randomly.

Pair Corralation between CERo Therapeutics and Cyclacel Pharmaceuticals

Assuming the 90 days horizon CERo Therapeutics Holdings is expected to generate 7.46 times more return on investment than Cyclacel Pharmaceuticals. However, CERo Therapeutics is 7.46 times more volatile than Cyclacel Pharmaceuticals. It trades about 0.05 of its potential returns per unit of risk. Cyclacel Pharmaceuticals is currently generating about -0.16 per unit of risk. If you would invest  1.83  in CERo Therapeutics Holdings on September 16, 2024 and sell it today you would lose (0.63) from holding CERo Therapeutics Holdings or give up 34.43% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

CERo Therapeutics Holdings  vs.  Cyclacel Pharmaceuticals

 Performance 
       Timeline  
CERo Therapeutics 

Risk-Adjusted Performance

14 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in CERo Therapeutics Holdings are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, CERo Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.
Cyclacel Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Cyclacel Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Even with inconsistent performance in the last few months, the Preferred Stock's fundamental indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

CERo Therapeutics and Cyclacel Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with CERo Therapeutics and Cyclacel Pharmaceuticals

The main advantage of trading using opposite CERo Therapeutics and Cyclacel Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if CERo Therapeutics position performs unexpectedly, Cyclacel Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuticals will offset losses from the drop in Cyclacel Pharmaceuticals' long position.
The idea behind CERo Therapeutics Holdings and Cyclacel Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Other Complementary Tools

Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum